High Dose Trial in COPD
Public ClinicalTrials.gov record NCT00128440. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multiple-dose, Double-Blind, Crossover Study to Compare the Efficacy and Safety of 200 μg and 400 μg of BEA 2180 BR to Tiotropium 5 μg and Placebo When Each is Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study was to compare the efficacy and safety of 200 μg and 400 μg of BEA 2180 BR to tiotropium 5 μg and placebo when each was delivered by the Respimat® Inhaler once daily for four weeks in patients with COPD.
Study identification
- NCT ID
- NCT00128440
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 78 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 84 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2005 (Type not available)
- Primary completion
- Sep 2006 (Actual)
- Completion
- Not listed
- Last update posted
- Oct 29, 2013
Started 2005
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Boehringer Ingelheim Investigational Site | Lakewood | California | — | — |
| Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| Boehringer Ingelheim Investigational Site | Pembroke Farms | Florida | — | — |
| Boehringer Ingelheim Investigational Site | Coeur d'Alene | Idaho | — | — |
| Boehringer Ingelheim Investigational Site | Reno | Nevada | — | — |
| Boehringer Ingelheim Investigational Site | Larchmont | New York | — | — |
| Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| Boehringer Ingelheim Investigational Site | Harker Heights | Texas | — | — |
| Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00128440, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2013 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00128440 live on ClinicalTrials.gov.